Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Adult Stem Cell Research Center and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Stem Cell Res Ther. 2020 Sep 14;11(1):397. doi: 10.1186/s13287-020-01920-3.
Mesenchymal stem cells (MSCs) have recently been considered a promising alternative treatment for diverse immune disorders due to their unique biomedical potentials including the immunomodulatory property and ability to promote tissue regeneration. However, despite many years of pre-clinical studies in the research field, results from clinical trials using these cells have been diverse and conflicting. This discrepancy is caused by several factors such as poor engraftment, low survival rate, and donor-dependent variation of the cells. Enhancement of consistency and efficacy of MSCs remains a challenge to overcome the current obstacles to MSC-based therapy and subsequently achieve an improved therapeutic outcome. In this review, we investigated function enhancement strategies by categorizing as preconditioning, genetic manipulation, usage of supportive materials, and co-administration with currently used drugs. Preconditioning prior to MSC application makes up a large proportion of improvement strategies and preconditioning reagents include bioactive substances (cytokines, growth factors, and innate immune receptor agonists), hypoxia, and modification in culture method. With the piled results from previous studies using each method, disease- or patient-specific therapy has become more important than ever. On the other hand, genetic manipulation targeting therapeutic-associated factors or co-administration of biocompatible materials has also arisen as other therapeutic strategies. Thus, we summarized several specialized tactics by analyzing up-to-date results in the field and proposed some promising enhancement methods to improve the clinical outcomes for MSC therapy.
间充质干细胞(MSCs)由于其独特的生物医学潜力,包括免疫调节特性和促进组织再生的能力,最近被认为是治疗多种免疫疾病的有前途的替代方法。然而,尽管在研究领域进行了多年的临床前研究,但使用这些细胞的临床试验结果却多种多样,相互矛盾。这种差异是由多种因素引起的,例如植入不良、存活率低以及供体细胞的差异。提高 MSCs 的一致性和疗效仍然是克服基于 MSC 治疗当前障碍的挑战,从而实现改善的治疗结果。在这篇综述中,我们通过分类为预处理、遗传操作、使用支持材料以及与当前使用的药物联合使用,研究了功能增强策略。在 MSC 应用之前进行预处理构成了大多数改进策略,预处理试剂包括生物活性物质(细胞因子、生长因子和先天免疫受体激动剂)、缺氧和培养方法的改变。随着每种方法的前期研究结果的积累,针对特定疾病或患者的治疗比以往任何时候都更加重要。另一方面,针对治疗相关因素的遗传操作或生物相容性材料的联合使用也已经成为其他治疗策略。因此,我们通过分析该领域的最新结果总结了几种专门的策略,并提出了一些有前途的增强方法,以改善 MSC 治疗的临床结果。